Strategic partnerships Leverage Altis’s RepliGut human intestinal models and recent CN Bio integration to propose joint ADME and organ-on-a-chip collaborations with pharma companies seeking integrated gut-liver physiology insights for safer, faster preclinical programs.

Global expansion Highlight opportunities in in vitro GI models across pharmaceutical pipelines, especially for oral drug delivery and toxicity screening, aligning with Altis’s plan to reduce animal testing and support large-scale preclinical programs.

Clinical relevance Position RepliGut Planar and InflammaScreen services as critical readouts for inflammation, permeability, and gut-specific toxicity to address late-stage attrition and improve translational predictability for GI-targeted therapies.

Industry credibility Utilize Altis’s NIH-backed microfluidic colon work and collaborations with top pharma to open conversations about contract research services, customization, and data transparency that can differentiate from traditional cell lines.

Technology moat Pitch access to donor-derived human intestinal cells and region-specific RepliGut models as a unique asset for compound screening, disease modeling, and pharmacokinetic analysis, enabling faster lead optimization and readouts with human-relevant biology.